Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This vaccine is an adjuvanted subunit vaccine derived from eggs, designed to provide active immunization against the 2009 pandemic swine-origin Influenza A (H1N1) virus. The vaccine consists of purified, inactivated split virion particles of the H1N1 virus (A/California/7/2009 strain) propagated in embryonated chicken eggs. The addition of an adjuvant (commonly MF59 or AS03, but exact adjuvant not specified for this exact formulation) enhances immunogenicity. The mechanism of action involves induction of strain-specific humoral and cell-mediated immunity primarily targeting the viral hemagglutinin protein, resulting in protection against H1N1 infection. The primary indication is the prevention of pandemic Influenza A (H1N1) in all age groups[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adjuvanted swine-origin A (H1N1) pandemic subunit egg-derived vaccine.